{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:04Z","timestamp":1787008624596,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurologic Disorders and Stroke","doi-asserted-by":"crossref","award":["K23 NS110470"],"award-info":[{"award-number":["K23 NS110470"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurologic Disorders and Stroke","doi-asserted-by":"crossref","award":["R01NS086312"],"award-info":[{"award-number":["R01NS086312"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurologic Disorders and Stroke","doi-asserted-by":"crossref","award":["R01NS110519"],"award-info":[{"award-number":["R01NS110519"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW009345"],"award-info":[{"award-number":["D43TW009345"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002492"],"award-info":[{"award-number":["KL2TR002492"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"larger AMBITION-cm trial","award":["TRIA2015-1092"],"award-info":[{"award-number":["TRIA2015-1092"]}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Global Health Trials scheme","award":["MR\/P006922\/1"],"award-info":[{"award-number":["MR\/P006922\/1"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited data exist on the antifungal activity of daily liposomal amphotericin B with flucytosine induction regimens for cryptococcal meningitis, which are recommended in high-income countries. Liposomal amphotericin B monotherapy at 3 mg\/kg previously failed to meet noninferiority criteria compared to amphotericin B deoxycholate in its registrational clinical trial. We aimed to compare the quantitative antifungal activity and mortality between daily amphotericin B deoxycholate and daily liposomal amphotericin B among persons with human immunodeficiency virus (HIV)\u2013related cryptococcal meningitis receiving adjunctive flucytosine 100 mg\/kg\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from 3 clinical studies involving participants with HIV-associated cryptococcal meningitis receiving either daily liposomal amphotericin B at 3 mg\/kg\/day with flucytosine (n = 94) or amphotericin B deoxycholate at 0.7\u20131.0 mg\/kg\/day with flucytosine (n = 404) as induction therapy. We compared participant baseline characteristics, cerebrospinal fluid (CSF) early fungicidal activity (EFA), and 10-week mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 498 participants in this analysis, of whom 201 had available EFA data (n = 46 liposomal amphotericin B; n = 155 amphotericin B deoxycholate). Overall, there is no statistical evidence that the antifungal activity of liposomal amphotericin B (mean EFA, 0.495 [95% confidence interval {CI}, .355\u2013.634] log10 colony-forming units [CFU]\/mL\/day) differ from amphotericin B deoxycholate (mean EFA, 0.402 [95% CI, .360\u2013.445] log10 CFU\/mL) (P = .13). Mortality at 10 weeks trended lower for liposomal amphotericin B (28.2%) versus amphotericin B deoxycholate (34.6%) but was not statistically different when adjusting for baseline characteristics (adjusted hazard ratio, 0.74 [95% CI, .44\u20131.25]; P = .26).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daily liposomal amphotericin B induction demonstrated a similar rate of CSF fungal clearance and 10-week mortality as amphotericin B deoxycholate when combined with flucytosine for the treatment of HIV-associated cryptococcal meningitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae326","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:34:46Z","timestamp":1719311686000},"page":"153-159","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1335-9787","authenticated-orcid":false,"given":"Sarah","family":"Kimuda","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kwizera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyue","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Kigozi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]},{"name":"Department of Clinical Epidemiology and Biostatistics, School of Medicine, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Kasozi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris K","family":"Rutakingirwa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmus","family":"Tukundane","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabbaale","family":"Shifah","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Luggya","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Luswata","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Frances","family":"Ndyetukira","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer L","family":"Yueh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Mulwana","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduljewad","family":"Wele","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C","family":"Bahr","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Meya","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]},{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Boulware","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb P","family":"Skipper","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]},{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"2025020710473812300_ciae326-B1","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025020710473812300_ciae326-B2","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/QAI.0b013e31828e1e56","article-title":"Cost-effective diagnostic checklists for meningitis in resource-limited settings","volume":"63","author":"Durski","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025020710473812300_ciae326-B3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11011-013-9476-1","article-title":"Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study","volume":"29","author":"Carlson","year":"2014","journal-title":"Metab Brain Dis"},{"key":"2025020710473812300_ciae326-B4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mmcr.2023.04.001","article-title":"Persistently elevated intracranial pressure in cryptococcal meningitis\u201476 therapeutic lumbar punctures","volume":"40","author":"Jjunju","year":"2023","journal-title":"Med Mycol Case Rep"},{"key":"2025020710473812300_ciae326-B5","article-title":". Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV","author":"World Health Organization","year":"2022"},{"key":"2025020710473812300_ciae326-B6","article-title":"Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","author":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV","year":"2021"},{"key":"2025020710473812300_ciae326-B7","article-title":"AmBisome (amphotericin B) liposome for injection. FDA package insert","author":"US Food and Drug Administration","year":"2008"},{"key":"2025020710473812300_ciae326-B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B9","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciaa016","article-title":"Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials","volume":"71","author":"Pullen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2025020710473812300_ciae326-B11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3201\/eid2001.130906","article-title":"Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast","volume":"20","author":"Boulware","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2025020710473812300_ciae326-B13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/mmy\/myv104","article-title":"Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis","volume":"54","author":"Dyal","year":"2016","journal-title":"Med Mycol"},{"key":"2025020710473812300_ciae326-B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2025020710473812300_ciae326-B15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/biostatistics\/kxt050","article-title":"Predicting the restricted mean event time with the subject's baseline covariates in survival analysis","volume":"15","author":"Tian","year":"2014","journal-title":"Biostatistics"},{"key":"2025020710473812300_ciae326-B16","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"Longley","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B18","doi-asserted-by":"publisher","DOI":"10.1016\/S473-3099(23)00731-4","article-title":"Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM [manuscript published online ahead of print 9 February 2024]","author":"Chang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025020710473812300_ciae326-B19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"2025020710473812300_ciae326-B20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cir745","article-title":"Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis","volume":"54","author":"Loyse","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N Engl J Med"},{"key":"2025020710473812300_ciae326-B22","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","article-title":"Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy","volume":"46","author":"Kambugu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N Engl J Med"},{"key":"2025020710473812300_ciae326-B24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025020710473812300_ciae326-B25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025020710473812300_ciae326-B26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/jof9010046","article-title":"Sterile cerebrospinal fluid culture at cryptococcal meningitis diagnosis is associated with high mortality","volume":"9","author":"Skipper","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2025020710473812300_ciae326-B27","doi-asserted-by":"crossref","first-page":"ofu070","DOI":"10.1093\/ofid\/ofu070","article-title":"Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings","volume":"1","author":"Bahr","year":"2014","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae326\/58702428\/ciae326.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/153\/58702428\/ciae326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/153\/58702428\/ciae326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:48:14Z","timestamp":1738907294000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/153\/7701737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,29]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae326","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,6,29]]}}}